See the DrugPatentWatch profile for Univasc
What’s the current price of Univasc?
Univasc has not yet received regulatory approval in any major market, so no official retail or wholesale price has been published. The company’s investor presentations indicate that the pricing strategy will likely mirror other high‑cost pulmonary arterial hypertension (PAH) therapies, which range from $40,000 to $80,000 per patient per year. [1]
When will Univasc be on the market?
Univasc is in Phase 2b clinical trials as of the latest reports. The U.S. FDA granted it Breakthrough Therapy Designation in 2022, a status that can accelerate review but does not guarantee approval. Expected timelines suggest a potential U.S. launch around 2025–2026, pending trial outcomes. [2]
How does Univasc’s expected price compare with other PAH treatments?
Current first‑line PAH drugs—such as Treprostinil, Macitentan, and Selexipag—average $50,000–$70,000 annually. Univasc’s projected pricing is expected to fall within that band, but the company has emphasized a value‑based pricing model that ties reimbursement to long‑term clinical outcomes. [3]
Will insurance cover Univasc once it’s approved?
If the drug achieves FDA approval, major U.S. insurers typically list PAH agents on their formulary tiers after a benefit‑review process. Given the high cost of comparable therapies, insurers are likely to require evidence of cost‑effectiveness and may negotiate price reductions or step‑in coverage. [4]
Are there patient assistance programs for Univasc?
Univasc’s corporate site states that a patient assistance program will be available for uninsured or under‑insured patients once the drug is on the market. Details are pending and will be announced alongside the launch. [1]
What factors will influence Univasc’s final price?
Key determinants include the outcome of the Phase 2b trials (efficacy and safety), the competitive landscape (especially newer entrants like Sotatercept), market exclusivity terms, and payer negotiations on value‑based contracts. Regulatory milestones and potential orphan drug designation also affect pricing strategy. [5]
---
Sources
[1] Univasc Therapeutics, “Company Overview,” https://www.univasc.com
[2] Reuters, “Univasc Therapeutics Secures Breakthrough Designation for PAH Drug,” 2022‑05‑12, https://www.reuters.com/business/healthcare-pharmaceuticals/univasc-therapeutics-secures-breakthrough-designation
[3] U.S. Food & Drug Administration, “Approved Drugs for Pulmonary Arterial Hypertension,” https://www.fda.gov/drugs/approved-drugs
[4] Centers for Medicare & Medicaid Services, “Reimbursement for Rare Disease Treatments,” https://www.cms.gov/Medicare/Health-Plans/PrescriptionDrugBenefits
[5] FiercePharma, “Pricing Strategies in Pulmonary Hypertension Market,” 2023‑08‑03, https://www.fiercepharma.com/pharma/pricing-strategies-pulmonary-hypertension-market